• XBiotech today announced positive final Phase II TASKIN results for vilamakitug in refractory metastatic colorectal cancer, meeting the prespecified primary efficacy criterion.
• The trial evaluated vilamakitug added to standard treatment; an exploratory analysis showed a statistically significant survival benefit in patients with right-sided tumors.
• The findings support a focus on right-sided disease as vilamakitug advances toward registrational clinical development.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. XBiotech Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610190900PRIMZONEFULLFEED9848126) on October 19, 2026, and is solely responsible for the information contained therein.